<DOC>
	<DOCNO>NCT02213861</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability SHAPE administer topically skin lesion patient early-stage cutaneous T-cell lymphoma ( CTCL ) .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Study SHAPE IA , IB IIA Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>This Phase 2 , multicenter , open-label , randomize study evaluate efficacy safety SHAPE Gelled Solution apply topically daily twice daily 26 consecutive week specify skin lesion patient Stage IA , IB IIA CTCL . Patients respond treatment allow continue study maximum 52 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histological confirmation CTCL ; document verifiable biopsy report require Documented clinical stage IA , IB IIA CTCL Skin lesion involvement least 2 % BSA accessible topical application study drug ECOG performance status 02 CTCL histologic evidence folliculotropic variant large cell transform CTCL Palpable lymph node â‰¥1.5 cm diameter ( unless lymph node biopsied designated Stage IAIIA disease ) Coexistent second malignancy history prior solid organ malignancy within previous 5 year ( exclude basal squamous cell carcinoma , situ carcinoma cervix ( CIN3 ) , papillary follicular thyroid cancer prostate cancer treat curatively Any prior history hematologic malignancy ( CTCL ) within past 5 year CTCL disease know refractory systemic histone deacetylase inhibitor Prior concurrent central nervous system ( CNS ) metastases History current major gastrointestinal , pulmonary , cardiovascular , genitourinary hematologic disease , CNS disorder , infectious disease coagulation disorder determine Investigator Evidence active Hepatitis B C HIV Circulating atypical cell clinical significance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CTCL</keyword>
	<keyword>Cutaneous T-Cell Lymphoma</keyword>
	<keyword>Early-stage</keyword>
	<keyword>SHAPE</keyword>
	<keyword>SHP-141</keyword>
	<keyword>topical</keyword>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>CAILS</keyword>
	<keyword>mSWAT</keyword>
	<keyword>mycosis fungoides</keyword>
</DOC>